Geneva, Switzerland,  January 31, 2020 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases (the “Company”), today announced the successful completion of a €17.5 million international private placement only to certain qualified and institutional investors of 5,932,201 new ordinary bearer shares of GeNeuro with a par value of CHF 0.05 each (the “New Shares” and the “Offering”, respectively).

For more information,